your market intelligence analyst
Search Results
121 results
Your search is now limited to «Bladder Cancer» expert search.
Approximately 25 percent of bladder cancer initially presents as muscle-invasive bladder cancer, which is when the cancer cells have spread beyond the inner lining of the bladder and into the muscle layer.
More from Medical Xpress - Medical Research News: 10/21/2019 08:11
Condition : Invasive Bladder Cancer Interventions : Drug: Atezolizumab; Drug: BCG Sponsors : Fundacion Oncosur; Apices Soluciones S.L. Not yet recruiting.
More from
The purpose of this guidance is to assist sponsors in the development of drugs, including biologics, for the treatment of patients who have bacillus Calmette-Guérin (BCG)-unresponsive nonmuscle invasive bladder cancer (NMIBC.
More from U.S. Food & Drug Administration - FDA - What's New: Drugs (FDA):
GlobeNewswire 10/18/2019 10:16
COPENHAGEN, Denmark, October 18, 2019 – Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the stage 1 of the Phase 2 study evaluating the combination therapy of its cancer immunotherapy, CV301, and Roches’s checkpoint inhibitor, atezolizumab (TECENTRIQ ® ), for the treatment of patients with locally advanced or metastatic urothelial bladder cancer did not meet the efficacy threshold to progress into stage 2 with expanded enrollment.
More from GlobeNewswire:
Healio News 10/16/2019 08:00
This makes bladder cancer the costliest cancer of all cancer types.
More from Healio News:
miR-204 Negatively Regulates Cell Growth And Metastasis By Targeting ROBO4 In Human Bladder Cancer.
More from International Journal of COPD:
BIOENGINEER.ORG 10/15/2019 12:59
Previous studies indicate that treatment with chemotherapeutic agents and targeted therapies, such as RTKIs, increased COX-2 expression in bladder cancer cells, glioma cancer stem cells, non-small cell lung cancer, and oral squamous cell carcinoma cells in vitro.
More from BIOENGINEER.ORG: 10/10/2019 15:20
Mutation and inactivation of the tumor suppressor TSC1 has been found in approximately 15% of bladder cancers and loss of heterozygosity of a region spanning the TSC1 locus at 9q34 has been seen in roughly 54% of bladder cancers.
More from
EurekAlert 10/10/2019
Mutation and inactivation of the tumor suppressor TSC1 has been found in approximately 15% of bladder cancers and loss of heterozygosity of a region spanning the TSC1 locus at 9q34 has been seen in roughly 54% of bladder cancers.
More from EurekAlert:
Targeted Oncology 10/02/2019 20:39
Patients with bladder and transitional cell carcinoma of the upper tract frequently have renal dysfunction.
More from Targeted Oncology:
Purpose:. The CANON [ CA VATAK in NON –muscle-invasive bladder cancer (NMIBC)] study evaluated a novel ICAM-1–targeted immunotherapeutic-coxsackievirus A21 as a novel oncolytic agent against bladder cancer. Patients and Methods:. Fifteen patients enrolled in this "window of opportunity" phase I study, exposing primary bladder cancers to CAVATAK prior to surgery.
More from Clinical Cancer Research - Recent Issues (abstracts):
PubMed News (NIH) 10/01/2019
Contributors : Di Liu ; XinYao Qiu Series Type : Non-coding RNA profiling by array Organism : Homo sapiens ; synthetic construct. Piperlongumine (PL), a natural alkaloid isolated from longer pepper plants, is recently found to be a potent selective anti-cancer compound.
More from PubMed News (NIH):

Therapeutic Areas

Clinical Trials and Phases

Business Issues

Companies - Public

Companies - Venture Funded

Financial Results

Global Markets

Global Risk Factors

Government Agencies

Job Titles

Legal and Regulatory

Cell Receptors


Diagnostics and Therapeutics


Drugs - Brand Names

Drugs - Generic



Health Care

Health and Wellness

Human Anatomy

Mechanisms of Action

Medical Devices



Strategic Scenarios



On this page, you see the results of the search you have run.  You may also view the following:

  •  Click on this drop-down menu on the right hand side of the page, to choose between the machine learning-produced Insights Reports, or the listing of concepts extracted from the results, in chart or list format. 

  •  View the number of search results returned for the search in each of your collections, and click on any of those numbers to view the entire listing of results from the chosen collection.

  •  Use the search adjustment drop-downs to change the scope, sorting, and presentation of your results.

  •  Show or hide the record’s caption (content description).

  •  Show actions that can be made with the search result record.

  •  Click on the Save button after running your search, to save it so that its results will be updated each time relevant new content is added to the designated collection. You may choose to be notified via search alerts.

Click here for more info on Search Results

Click here for more info on Machine Learning applications